Faes Farma, S.A. (FRA:FFEA)

Germany flag Germany · Delayed Price · Currency is EUR
4.510
0.00 (0.00%)
Last updated: Jun 3, 2026, 8:04 AM CET
Market Cap1.41B +6.3%
Revenue (ttm)674.06M +28.6%
Net Income82.04M -24.9%
EPS0.26
Shares Out n/a
PE Ratio17.17
Forward PE14.07
Dividend0.10 (2.30%)
Ex-Dividend DateJun 23, 2026
Volumen/a
Open4.510
Previous Close4.510
Day's Range4.510 - 4.510
52-Week Range4.100 - 5.490
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 27, 2026

About Faes Farma

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securiti... [Read more]

Industry Pharmaceutical Preparations
Founded 1933
Employees 2,681
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol FFEA

Financial Performance

In 2025, Faes Farma's revenue was 626.99 million, an increase of 22.93% compared to the previous year's 510.04 million. Earnings were 79.63 million, a decrease of -28.49%.

Financial Statements

News

Faes Farma Earnings Call Transcript: Q1 2026

Revenue grew 31% year-over-year to EUR 200.1 million, with strong organic and acquisition-driven growth. Net profit rose 9%, and guidance for 2026 is maintained despite expected headwinds from Bilastine generics in Japan.

4 weeks ago - Transcripts

Faes Farma Slides: Q1 2026

Faes Farma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.

4 weeks ago - Filings

Faes Farma Earnings release: Q1 2026

Faes Farma released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Faes Farma Earnings Call Transcript: Q4 2025

2025 saw 23% revenue growth, major acquisitions, and strong international expansion, with adjusted EBITDA up 3.1% and net profit down due to one-offs. 2026 guidance targets 17%-19% revenue and 28%-31% EBITDA growth, with continued focus on integration, efficiency, and international markets.

3 months ago - Transcripts

Faes Farma Earnings release: Q4 2025

Faes Farma released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.

3 months ago - Filings

Faes Farma Slides: Q4 2025

Faes Farma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.

3 months ago - Filings

Faes Farma Quarterly report: Q3 2025

Faes Farma has published its Q3 2025 quarterly earnings report on November 4, 2025.

7 months ago - Filings

Faes Farma Slides: Q3 2025

Faes Farma has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.

7 months ago - Filings

Faes Farma Quarterly report: Q2 2025

Faes Farma has published its Q2 2025 quarterly earnings report on July 24, 2025.

11 months ago - Filings

Faes Farma Slides: Q2 2025

Faes Farma has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 24, 2025.

11 months ago - Filings

Faes Farma Transcript: M&A Announcement

The acquisition of SIFI accelerates the 2030 growth strategy, expanding the ophthalmology portfolio, global reach, and R&D pipeline. The €270 million deal is expected to be EPS accretive from year one, with strong synergies, high-margin businesses, and limited competition in key areas.

1 year ago - Transcripts

Faes Farma Press release: M&A Announcement

Faes Farma issued a press release on June 11, 2025, disclosing material business information to investors.

1 year ago - Filings

Faes Farma Slides: M&A Announcement

Faes Farma has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2025.

1 year ago - Filings